PDCD1 and kidney cancer: Survival analysis showed that patients with low NUSAP1 levels exhibited improved PFS in NSCLC) and OS in kidney cancer and SKCM when treated with anti-PD-1/PD-L1 therapy, compared to those with high NUSAP1 levels (Figure 7E and Supplementary Figure S6).